EXEL
Exelixis Inc
NASDAQ: EXEL · HEALTHCARE · BIOTECHNOLOGY
$44.46
-0.51% today
Updated 2026-04-30
Market cap
$11.35B
P/E ratio
16.08
P/S ratio
4.89x
EPS (TTM)
$2.78
Dividend yield
—
52W range
$34 – $50
Volume
2.7M
WallStSmart proprietary scores
70
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A7.8
Quality
B+10.0
Profitability
A+7.3
Valuation
B+5/9
Piotroski F-Score
Moderate
4.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$47.53
+6.91%
12-Month target
$41.91
-5.74%
Intrinsic (DCF)
$165.35
Margin of safety
+74.03%
1 Strong Buy9 Buy10 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 4.09 — safe zone
+ Profit margin 33.70% — above average
+ ROE 35.50% — strong efficiency
+ Free cash flow $332.36M — positive
+ 74.03% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.61B | $1.83B | $2.17B | $2.32B | $2.32B |
| Net income | $182.28M | $207.76M | $521.27M | $782.57M | $244.53M |
| EPS | — | — | — | — | $2.78 |
| Free cash flow | $224.16M | $170.35M | $633.79M | $844.34M | $332.36M |
| Profit margin | 11.31% | 11.35% | 24.04% | 33.73% | 33.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-26 | SENNER, CHRISTOPHER J. | Buy | 52,018 | — |
| 2026-02-26 | MORRISSEY, MICHAEL | Buy | 160,437 | — |
| 2026-02-26 | HEFTI, BRENDA | Buy | 23,119 | — |
Peer comparison
Smart narrative
Exelixis Inc trades at $44.46. representing a P/E of 16.08x trailing earnings. Our Smart Value Score of 70/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 4.09, it sits in the safe zone. TTM revenue stands at $2.32B. with profit margins at 33.70%. Our DCF model estimates intrinsic value at $165.35.
Frequently asked questions
What is Exelixis Inc's stock price?
Exelixis Inc (EXEL) trades at $44.46.
Is Exelixis Inc overvalued?
Smart Value Score 70/100 (Grade B, Buy). DCF value $165.35.
What is the price target of Exelixis Inc (EXEL)?
The analyst target price is $47.53, representing +6.9% upside from the current price of $44.46.
What is the intrinsic value of Exelixis Inc (EXEL)?
Based on our DCF model, intrinsic value is $165.35, a +74.0% margin of safety versus $44.46.
What is Exelixis Inc's revenue?
TTM revenue is $2.32B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
4.09 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.89x
ROE35.50%
Beta0.42
50D MA$43.30
200D MA$41.69
Shares out0.25B
Float0.21B
Short ratio—
Avg volume2.7M
Performance
1 week-2.95%
1 month+4.20%
3 months+5.70%
YTD+1.96%
1 year—
3 years—
5 years—